Raafat E.F. Fahim, Ph.D. Nabi Biopharmaceuticals 12276 Wilkins Avenue Rockville, MD 20852

Re: Nabi Biopharmaceuticals

Preliminary Proxy Statement on Schedule 14A

Filed December 7, 2009, as amended February 3, 2010

File No. 000-04829

Dear Dr. Fahim:

We have completed our review of the above proxy statement. We have no further comments at this time.

Sincerely,

Jeffrey P. Riedler Assistant Director

cc: Joseph E. Gilligan, Esq. Hogan & Hartson LLP Columbia Square 555 Thirteenth Street, NW Washington, DC 20004